Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Efficacy of PTCy after mismatched unrelated donor (MMUD) HCT is unknown. In this pilot clinical trial, we enrolled 38 patients with hematologic malignancies scheduled to undergo MMUD-HCT (≥6/8 HLA-matched donors) onto 1 of 2 conditioning strata: myeloablative using fludarabine and fractionated total...

Full description

Saved in:
Bibliographic Details
Published in:Blood Adv
Main Authors: Al Malki, Monzr M., Tsai, Ni-Chun, Palmer, Joycelynne, Mokhtari, Sally, Tsai, Weimin, Cao, Thai, Ali, Haris, Salhotra, Amandeep, Arslan, Shukaib, Aldoss, Ibrahim, Karras, Nicole, Karanes, Chatchada, Zain, Jasmine, Khaled, Samer, Stein, Anthony, Snyder, David, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2021
Subjects:
Transplantation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270662/
https://ncbi.nlm.nih.gov/pubmed/34156440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004192
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items